Imaging biomarkers for evaluating tumor response: RECIST and beyond

doi:10.1186/s40364-021-00306-8

CNU IR > Pharmacy and Science > Dept. of Health and Nutrition (including master's program) > Periodical Articles > Item 310902800/34396

Please use this identifier to cite or link to this item: https://ir.cnu.edu.tw/handle/310902800/34396

Title:	Imaging biomarkers for evaluating tumor response: RECIST and beyond
Authors:	Ko, Ching-Chung Yeh, Lee-Ren Kuo, Yu-Ting Chen, Jeon-Hor
Contributors:	Chi Mei Med Ctr, Dept Med Imaging Chia Nan Univ Pharm & Sci, Dept Hlth & Nutr I Shou Univ, E DA Hosp, Dept Radiol Kaohsiung Med Univ Hosp, Dept Med Imaging Univ Calif Irvine, Dept Radiol Sci, Tu & Yuan Ctr Funct Oncoimaging
Keywords:	RECIST Imaging biomarker Tumor response
Date:	2021
Issue Date:	2023-11-11 11:49:31 (UTC+8)
Publisher:	BMC
Abstract:	Response Evaluation Criteria in Solid Tumors (RECIST) is the gold standard for assessment of treatment response in solid tumors. Morphologic change of tumor size evaluated by RECIST is often correlated with survival length and has been considered as a surrogate endpoint of therapeutic efficacy. However, the detection of morphologic change alone may not be sufficient for assessing response to new anti-cancer medication in all solid tumors. During the past fifteen years, several molecular-targeted therapies and immunotherapies have emerged in cancer treatment which work by disrupting signaling pathways and inhibited cell growth. Tumor necrosis or lack of tumor progression is associated with a good therapeutic response even in the absence of tumor shrinkage. Therefore, the use of unmodified RECIST criteria to estimate morphological changes of tumor alone may not be sufficient to estimate tumor response for these new anti-cancer drugs. Several studies have reported the low reliability of RECIST in evaluating treatment response in different tumors such as hepatocellular carcinoma, lung cancer, prostate cancer, brain glioma, bone metastasis, and lymphoma. There is an increased need for new medical imaging biomarkers, considering the changes in tumor viability, metabolic activity, and attenuation, which are related to early tumor response. Promising imaging techniques, beyond RECIST, include dynamic contrast-enhanced computed tomography (CT) or magnetic resonance imaging (MRI), diffusion-weight imaging (DWI), magnetic resonance spectroscopy (MRS), and (18) F-fluorodeoxyglucose (FDG) positron emission tomography (PET). This review outlines the current RECIST with their limitations and the new emerging concepts of imaging biomarkers in oncology.
Relation:	BIOMARK RES, v.9, n.1
Appears in Collections:	[Dept. of Health and Nutrition (including master's program)] Periodical Articles

Files in This Item:

File	Description	Size	Format
index.html		0Kb	HTML	162	View/Open
s40364-021-00306-8.pdf		4628Kb	Adobe PDF	103	View/Open

Loading...